Replies to post #23178 on Innovation Pharmaceuticals Inc (IPIX)

[ICEVRE3]

I believe..
we see a dip/weakness the next few weeks.
We've had strength the last few weeks which kept us afloat. This news boosts us up a few points with a slow trickle back to 2 and we zig-zag btwn 1.90-2.10 until something substantial is released. I'd love to be proved wrong and see steady accumulation so let it be,but; my 2 cents. NYR2 keyed me into this ticker mid-DEC and I've payed holiday bills with the profits, much thanks :) Looks good long-term though, love this ticker. I'm a small fish but I support strength and help push momo so fingers x'd for positive results.

Thank you management.

Watching like a hawk here..

[JB3729]

I agree and feel this PR is the most significant yet -

Not sure why the PR is being overly downplayed. This was the first trial update in 7 weeks and the news is awesome!

The ASCO meeting gives Cellceutix an opportunity to provide a comprehensive update on the latest data from the Kevetrin clinical trials to shareholders and leaders in the scientific community as well as time for interaction with others about possible future collaborations and studies. IMO, this exudes confidence that the trials will run smoothly and produce the desired results.

Dr. Krishna Menon, Chief Scientific Officer at Cellceutix, commented, “We are still at the early stages of the clinical trial. To date, we have not observed any dose limiting toxicities. Initial pharmacokinetic (PK) data from the clinical trial has been received and is consistent with the animal data, which is a very optimistic sign moving forward. Additional information on these PK studies will be forthcoming at ASCO. We are now looking forward to receiving data from the p21 biomarker studies which is expected in March 2013.”

Terrific trial update and as Leo says - http://cellceutix.com/best-yet-to-come/